| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
20-Gluco-ginsenoside-Rf is a bioactive ginsenoside that may interact with various molecular targets including nuclear receptors, ion channels, and signaling proteins. Ginsenosides are known to exert diverse pharmacological effects including anti-inflammatory, antioxidant, and neuroprotective activities. As a PPT-type saponin, it may modulate cellular signaling pathways through interactions with membrane receptors and intracellular targets.
|
|---|---|
| ln Vitro |
In vitro studies have evaluated 20-gluco-ginsenoside-Rf for various biological activities. As a ginsenoside, it may exhibit anti-inflammatory, antioxidant, and neuroprotective effects in cell-based assays. The compound is typically dissolved in DMSO or ethanol and diluted in cell culture medium for testing. Cellular responses are assessed using assays for viability, proliferation, apoptosis, or specific signaling pathway markers.
|
| ln Vivo |
In vivo activity of 20-gluco-ginsenoside-Rf has been studied in animal models. As a ginseng-derived saponin, it may exhibit various pharmacological effects including anti-inflammatory, immunomodulatory, and neuroprotective activities. The compound is typically administered via oral, intraperitoneal, or intravenous routes. Dosing regimens vary depending on the specific study objectives and animal model used.
|
| Enzyme Assay |
For non-cellular assays, 20-gluco-ginsenoside-Rf is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated in various biochemical assays including enzyme inhibition studies, receptor binding assays, and antioxidant activity tests. Typical protocols involve dissolving the compound in appropriate solvents and analyzing by chromatographic methods. Purity is typically ≥98%.
|
| Cell Assay |
For in vitro cell-based studies, 20-gluco-ginsenoside-Rf is dissolved in DMSO or ethanol and diluted in cell culture medium to appropriate concentrations. Cells are cultured under standard conditions and treated with the compound for various time points. Cellular responses are assessed using assays for viability, proliferation, apoptosis, or specific signaling pathway markers. Appropriate controls including vehicle controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, 20-gluco-ginsenoside-Rf is administered via various routes including oral gavage, intraperitoneal injection, or intravenous injection depending on the study design. Dosing solutions are prepared using appropriate vehicles. The compound is evaluated in animal models of inflammation, neurodegeneration, or other disease states. Dosing regimens and administration protocols follow approved animal welfare guidelines and institutional protocols.
|
| ADME/Pharmacokinetics |
20-Gluco-ginsenoside-Rf has a molecular weight of 963.15 and molecular formula C48H82O19. Storage: typically stored at -20°C. The compound is a natural product found in Panax ginseng and Panax notoginseng. It is a bisdesmosidic saponin and a protopanaxatriol (PPT)-type ginsenoside. The compound should be stored in a sealed container protected from light and moisture.
|
| Toxicity/Toxicokinetics |
20-Gluco-ginsenoside-Rf is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. As a natural product, it may have pharmacological activities at certain concentrations. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| References | |
| Additional Infomation |
Ginsenoside Rd has been reported to exist in ginseng (Panax japonicus), gynostemma pentaphyllum, and other organisms with relevant data. See also: Ginsenoside Rd (note moved to).
20-Gluco-ginsenoside-Rf (CAS 68406-27-9) is also known as 20-glucoginsenoside Rf and is a bisdesmosidic saponin obtained from the roots of Panax ginseng. It is a naturally occurring, albeit minor, constituent of Panax ginseng roots and flower buds. The compound is a class of dammarane-type triterpenoid saponins used as a biochemical reagent. No clinical trials or therapeutic approvals exist for the purified compound. |
| Molecular Formula |
C48H82O19
|
|---|---|
| Molecular Weight |
963.15
|
| Exact Mass |
962.545
|
| CAS # |
68406-27-9
|
| PubChem CID |
24721561
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1045.5±65.0 °C at 760 mmHg
|
| Flash Point |
586.1±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.618
|
| LogP |
1.49
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@]2(C)[C@@H]1[C@@H](C[C@@H]3[C@@]4(C)CC[C@@H](C(C)(C)[C@@H]4[C@H](C[C@]32C)O[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@@H](CO)O6)O)O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@@H](CO)O7)O)O)O)C
|
| InChi Key |
FBFMBWCLBGQEBU-RXMALORBSA-N
|
| InChi Code |
InChI=1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)64-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(53)44(3,4)40(45)24(17-47(28,46)7)62-43-39(36(59)33(56)27(20-51)65-43)66-41-37(60)34(57)31(54)25(18-49)63-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
